{"count": 117, "results": [{"_id": "34421608", "pmid": 34421608, "pmcid": "PMC8373262", "title": "Metformin Potentiates the Effects of Anlotinib in NSCLC via AMPK/mTOR and ROS-Mediated Signaling Pathways", "journal": "Front Pharmacol", "authors": ["Zhu Z", "Jiang T", "Suo H", "Xu S", "Zhang C", "Ying G", "Yan Z"], "date": "2021-08-04T00:00:00Z", "doi": "10.3389/fphar.2021.712181", "meta_date_publication": "2021", "meta_volume": "12", "meta_issue": "", "meta_pages": "712181", "score": 50276.734, "text_hl": "Here, we evaluated the possible synergistic effect of @CHEMICAL_anlotinib @CHEMICAL_MESH:C000625192 @@@anlotinib@@@ and @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ in @<m>DISEASE_Carcinoma_Non_Small_Cell_Lung</m> @DISEASE_MESH:D002289 @@@NSCLC@@@ cells. ", "citations": {"NLM": "Zhu Z, Jiang T, Suo H, Xu S, Zhang C, Ying G, Yan Z. Metformin Potentiates the Effects of Anlotinib in NSCLC via AMPK/mTOR and ROS-Mediated Signaling Pathways Front Pharmacol. 2021;12():712181. PMID: 34421608", "BibTeX": "@article{34421608, title={Metformin Potentiates the Effects of Anlotinib in NSCLC via AMPK/mTOR and ROS-Mediated Signaling Pathways}, author={Zhu Z and Jiang T and Suo H and Xu S and Zhang C and Ying G and Yan Z}, journal={Front Pharmacol}, volume={12}, pages={712181}}"}}, {"_id": "36672573", "pmid": 36672573, "pmcid": "PMC9856116", "title": "Low-Dose Metformin Treatment Reduces In Vitro Growth of the LL/2 Non-small Cell Lung Cancer Cell Line", "journal": "Biomedicines", "authors": ["Bond NLS", "Dréau D", "Marriott I", "Bennett JM", "Turner MJ", "Arthur ST", "Marino JS"], "date": "2022-12-27T00:00:00Z", "doi": "10.3390/biomedicines11010065", "meta_date_publication": "2022 Dec 27", "meta_volume": "11", "meta_issue": "1", "meta_pages": "", "score": 50276.035, "text_hl": "...3.1. @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ Inhibited @<m>DISEASE_Carcinoma_Non_Small_Cell_Lung</m> @DISEASE_MESH:D002289 @@@NSCLC@@@ Cell Proliferation ", "citations": {"NLM": "Bond NLS, Dréau D, Marriott I, Bennett JM, Turner MJ, Arthur ST, Marino JS. Low-Dose Metformin Treatment Reduces In Vitro Growth of the LL/2 Non-small Cell Lung Cancer Cell Line Biomedicines. 2022 Dec 27;11(1):. PMID: 36672573", "BibTeX": "@article{36672573, title={Low-Dose Metformin Treatment Reduces In Vitro Growth of the LL/2 Non-small Cell Lung Cancer Cell Line}, author={Bond NLS and Dréau D and Marriott I and Bennett JM and Turner MJ and Arthur ST and Marino JS}, journal={Biomedicines}, volume={11}, number={1}}"}}, {"_id": "36199547", "pmid": 36199547, "pmcid": "PMC9527407", "title": "Metformin Synergizes with PD-L1 Monoclonal Antibody Enhancing Tumor Immune Response in Treating Non-Small Cell Lung Cancer and Its Molecular Mechanism Investigation", "journal": "Evid Based Complement Alternat Med", "authors": ["Wang Y", "Hu J", "Sun Y", "Song B", "Zhang Y", "Lu Y", "Ma H"], "date": "2022-09-25T00:00:00Z", "doi": "10.1155/2022/5983959", "meta_date_publication": "2022", "meta_volume": "2022", "meta_issue": "", "meta_pages": "5983959", "score": 50275.58, "text_hl": "We explore the efficacy of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ and @GENE_CD274 @GENE_60533 @@@PD-L1@@@ MAb in treating @<m>DISEASE_Carcinoma_Non_Small_Cell_Lung</m> @DISEASE_MESH:D002289 @@@NSCLC@@@ at the animal and cell levels and study the effect of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ combined with @GENE_CD274 @GENE_60533 @@@PD-L1@@@ MAb against @<m>DISEASE_Carcinoma_Non_Small_Cell_Lung</m> @DISEASE_MESH:D002289 @@@NSCLC@@@. ", "citations": {"NLM": "Wang Y, Hu J, Sun Y, Song B, Zhang Y, Lu Y, Ma H. Metformin Synergizes with PD-L1 Monoclonal Antibody Enhancing Tumor Immune Response in Treating Non-Small Cell Lung Cancer and Its Molecular Mechanism Investigation Evid Based Complement Alternat Med. 2022;2022():5983959. PMID: 36199547", "BibTeX": "@article{36199547, title={Metformin Synergizes with PD-L1 Monoclonal Antibody Enhancing Tumor Immune Response in Treating Non-Small Cell Lung Cancer and Its Molecular Mechanism Investigation}, author={Wang Y and Hu J and Sun Y and Song B and Zhang Y and Lu Y and Ma H}, journal={Evid Based Complement Alternat Med}, volume={2022}, pages={5983959}}"}}, {"_id": "36969876", "pmid": 36969876, "pmcid": "PMC10036803", "title": "Addition of metformin for non-small cell lung cancer patients receiving antineoplastic agents", "journal": "Front Pharmacol", "authors": ["Wang Y", "Hu Y", "Wang T", "Che G", "Li L"], "date": "2023-03-10T00:00:00Z", "doi": "10.3389/fphar.2023.1123834", "meta_date_publication": "2023", "meta_volume": "14", "meta_issue": "", "meta_pages": "1123834", "score": 50274.844, "text_hl": "Addition of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ for @<m>DISEASE_Carcinoma_Non_Small_Cell_Lung</m> @DISEASE_MESH:D002289 @@@non-small cell lung cancer@@@ @SPECIES_9606 @@@patients@@@ receiving antineoplastic agents", "citations": {"NLM": "Wang Y, Hu Y, Wang T, Che G, Li L. Addition of metformin for non-small cell lung cancer patients receiving antineoplastic agents Front Pharmacol. 2023;14():1123834. PMID: 36969876", "BibTeX": "@article{36969876, title={Addition of metformin for non-small cell lung cancer patients receiving antineoplastic agents}, author={Wang Y and Hu Y and Wang T and Che G and Li L}, journal={Front Pharmacol}, volume={14}, pages={1123834}}"}}, {"_id": "33489797", "pmid": 33489797, "pmcid": "PMC7815349", "title": "Metformin reverses chemoresistance in non-small cell lung cancer via accelerating ubiquitination-mediated degradation of Nrf2", "journal": "Transl Lung Cancer Res", "authors": ["Huang S", "He T", "Yang S", "Sheng H", "Tang X", "Bao F", "Wang Y", "Lin X", "Yu W", "Cheng F", "Lv W", "Hu J"], "date": "2020-12-01T00:00:00Z", "doi": "10.21037/tlcr-20-1072", "meta_date_publication": "2020 Dec", "meta_volume": "9", "meta_issue": "6", "meta_pages": "2337-2355", "score": 50270.59, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ reverses chemoresistance in @<m>DISEASE_Carcinoma_Non_Small_Cell_Lung</m> @DISEASE_MESH:D002289 @@@non-small cell lung cancer@@@ via accelerating ubiquitination-mediated degradation of Nrf2", "citations": {"NLM": "Huang S, He T, Yang S, Sheng H, Tang X, Bao F, Wang Y, Lin X, Yu W, Cheng F, Lv W, Hu J. Metformin reverses chemoresistance in non-small cell lung cancer via accelerating ubiquitination-mediated degradation of Nrf2 Transl Lung Cancer Res. 2020 Dec;9(6):2337-2355. PMID: 33489797", "BibTeX": "@article{33489797, title={Metformin reverses chemoresistance in non-small cell lung cancer via accelerating ubiquitination-mediated degradation of Nrf2}, author={Huang S and He T and Yang S and Sheng H and Tang X and Bao F and Wang Y and Lin X and Yu W and Cheng F and Lv W and Hu J}, journal={Transl Lung Cancer Res}, volume={9}, number={6}, pages={2337-2355}}"}}, {"_id": "36959680", "pmid": 36959680, "pmcid": "PMC10037810", "title": "Metformin regulates expression of DNA methyltransferases through the miR-148/-152 family in non-small lung cancer cells", "journal": "Clin Epigenetics", "authors": ["Lee BB", "Kim D", "Kim Y", "Han J", "Shim YM", "Kim DH"], "date": "2023-03-23T00:00:00Z", "doi": "10.1186/s13148-023-01466-0", "meta_date_publication": "2023 Mar 23", "meta_volume": "15", "meta_issue": "1", "meta_pages": "48", "score": 50268.24, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ regulates expression of DNA methyltransferases through the miR-148/-152 family in @<m>DISEASE_Carcinoma_Non_Small_Cell_Lung</m> @DISEASE_MESH:D002289 @@@non-small lung cancer@@@ cells", "citations": {"NLM": "Lee BB, Kim D, Kim Y, Han J, Shim YM, Kim DH. Metformin regulates expression of DNA methyltransferases through the miR-148/-152 family in non-small lung cancer cells Clin Epigenetics. 2023 Mar 23;15(1):48. PMID: 36959680", "BibTeX": "@article{36959680, title={Metformin regulates expression of DNA methyltransferases through the miR-148/-152 family in non-small lung cancer cells}, author={Lee BB and Kim D and Kim Y and Han J and Shim YM and Kim DH}, journal={Clin Epigenetics}, volume={15}, number={1}, pages={48}}"}}, {"_id": "33927955", "pmid": 33927955, "pmcid": "PMC8076758", "title": "Impact of Concurrent Coincident Use of Metformin During Lung Stereotactic Body Radiation Therapy", "journal": "Cureus", "authors": ["Stang K", "Alite F", "Adams W", "Altoos B", "Small C", "Melian E", "Emami B", "Harkenrider M"], "date": "2021-03-28T00:00:00Z", "doi": "10.7759/cureus.14157", "meta_date_publication": "2021 Mar 28", "meta_volume": "13", "meta_issue": "3", "meta_pages": "e14157", "score": 50267.91, "text_hl": "Recent data suggest synergy of chemoradiotherapy and @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ in locally-advanced @<m>DISEASE_Carcinoma_Non_Small_Cell_Lung</m> @DISEASE_MESH:D002289 @@@non-small cell lung cancer@@@ (@<m>DISEASE_Carcinoma_Non_Small_Cell_Lung</m> @DISEASE_MESH:D002289 @@@NSCLC@@@). ", "citations": {"NLM": "Stang K, Alite F, Adams W, Altoos B, Small C, Melian E, Emami B, Harkenrider M. Impact of Concurrent Coincident Use of Metformin During Lung Stereotactic Body Radiation Therapy Cureus. 2021 Mar 28;13(3):e14157. PMID: 33927955", "BibTeX": "@article{33927955, title={Impact of Concurrent Coincident Use of Metformin During Lung Stereotactic Body Radiation Therapy}, author={Stang K and Alite F and Adams W and Altoos B and Small C and Melian E and Emami B and Harkenrider M}, journal={Cureus}, volume={13}, number={3}, pages={e14157}}"}}, {"_id": "34235153", "pmid": 34235153, "pmcid": "PMC8255984", "title": "Additive Antiproliferative and Antiangiogenic Effects of Metformin and Pemetrexed in a Non-Small-Cell Lung Cancer Xenograft Model", "journal": "Front Cell Dev Biol", "authors": ["Wang JL", "Lan YW", "Tsai YT", "Chen YC", "Staniczek T", "Tsou YA", "Yen CC", "Chen CM"], "date": "2021-06-21T00:00:00Z", "doi": "10.3389/fcell.2021.688062", "meta_date_publication": "2021", "meta_volume": "9", "meta_issue": "", "meta_pages": "688062", "score": 50265.844, "text_hl": "Additive Antiproliferative and Antiangiogenic Effects of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ and @CHEMICAL_Pemetrexed @CHEMICAL_MESH:D000068437 @@@Pemetrexed@@@ in a @<m>DISEASE_Carcinoma_Non_Small_Cell_Lung</m> @DISEASE_MESH:D002289 @@@Non-Small-Cell Lung Cancer@@@ Xenograft Model", "citations": {"NLM": "Wang JL, Lan YW, Tsai YT, Chen YC, Staniczek T, Tsou YA, Yen CC, Chen CM. Additive Antiproliferative and Antiangiogenic Effects of Metformin and Pemetrexed in a Non-Small-Cell Lung Cancer Xenograft Model Front Cell Dev Biol. 2021;9():688062. PMID: 34235153", "BibTeX": "@article{34235153, title={Additive Antiproliferative and Antiangiogenic Effects of Metformin and Pemetrexed in a Non-Small-Cell Lung Cancer Xenograft Model}, author={Wang JL and Lan YW and Tsai YT and Chen YC and Staniczek T and Tsou YA and Yen CC and Chen CM}, journal={Front Cell Dev Biol}, volume={9}, pages={688062}}"}}, {"_id": "37405073", "pmid": 37405073, "pmcid": "PMC10315409", "title": "Efficacy of metformin adjunctive therapy as the treatment for non-diabetic patients with advanced non-small cell lung cancer: A Systematic review and Meta-analysis", "journal": "J Res Med Sci", "authors": ["Duan X", "Liao B", "Liu X", "Chen R"], "date": "2023-05-29T00:00:00Z", "doi": "10.4103/jrms.jrms_792_22", "meta_date_publication": "2023", "meta_volume": "28", "meta_issue": "", "meta_pages": "45", "score": 50264.89, "text_hl": "...@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ adjunctive therapy can improve the DCR of nondiabetic @SPECIES_9606 @@@patients@@@ with advanced @<m>DISEASE_Carcinoma_Non_Small_Cell_Lung</m> @DISEASE_MESH:D002289 @@@NSCLC@@@. ", "citations": {"NLM": "Duan X, Liao B, Liu X, Chen R. Efficacy of metformin adjunctive therapy as the treatment for non-diabetic patients with advanced non-small cell lung cancer: A Systematic review and Meta-analysis J Res Med Sci. 2023;28():45. PMID: 37405073", "BibTeX": "@article{37405073, title={Efficacy of metformin adjunctive therapy as the treatment for non-diabetic patients with advanced non-small cell lung cancer: A Systematic review and Meta-analysis}, author={Duan X and Liao B and Liu X and Chen R}, journal={J Res Med Sci}, volume={28}, pages={45}}"}}, {"_id": "33889509", "pmid": 33889509, "pmcid": "PMC8044488", "title": "Concurrent use of metformin enhances the efficacy of EGFR-TKIs in patients with advanced EGFR-mutant non-small cell lung cancer:an option for overcoming EGFR-TKI resistance", "journal": "Transl Lung Cancer Res", "authors": ["Han R", "Jia Y", "Li X", "Zhao C", "Zhao S", "Liu S", "Liu Y", "Chen D", "Zhang Q", "Liu X", "Shi J", "Li J", "Zhou C"], "date": "2021-03-01T00:00:00Z", "doi": "10.21037/tlcr-20-1153", "meta_date_publication": "2021 Mar", "meta_volume": "10", "meta_issue": "3", "meta_pages": "1277-1291", "score": 50264.754, "text_hl": "Only limited relevant clinical studies evaluated the therapeutic effects by combing @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ and @GENE_EGFR @GENE_1956 @@@EGFR@@@-TKIs in @<m>DISEASE_Carcinoma_Non_Small_Cell_Lung</m> @DISEASE_MESH:D002289 @@@non-small cell lung cancer@@@ (@<m>DISEASE_Carcinoma_Non_Small_Cell_Lung</m> @DISEASE_MESH:D002289 @@@NSCLC@@@) @SPECIES_9606 @@@patients@@@. ", "citations": {"NLM": "Han R, Jia Y, Li X, Zhao C, Zhao S, Liu S, Liu Y, Chen D, Zhang Q, Liu X, Shi J, Li J, Zhou C. Concurrent use of metformin enhances the efficacy of EGFR-TKIs in patients with advanced EGFR-mutant non-small cell lung cancer:an option for overcoming EGFR-TKI resistance Transl Lung Cancer Res. 2021 Mar;10(3):1277-1291. PMID: 33889509", "BibTeX": "@article{33889509, title={Concurrent use of metformin enhances the efficacy of EGFR-TKIs in patients with advanced EGFR-mutant non-small cell lung cancer:an option for overcoming EGFR-TKI resistance}, author={Han R and Jia Y and Li X and Zhao C and Zhao S and Liu S and Liu Y and Chen D and Zhang Q and Liu X and Shi J and Li J and Zhou C}, journal={Transl Lung Cancer Res}, volume={10}, number={3}, pages={1277-1291}}"}}]}